Evicenter
P&T meetings

Lirafugratinib (Lyrfigtu)

Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

Also known as RLY-4008
Regulatory submission
NDA submitted January 2026
Last updated
158 sources

Product information and disease descriptionPlace of product in therapyDisease description

Burden of Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

31 evidence topics · 19 sources